BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 21610040)

  • 1. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials.
    Boutitie F; Pinede L; Schulman S; Agnelli G; Raskob G; Julian J; Hirsh J; Kearon C
    BMJ; 2011 May; 342():d3036. PubMed ID: 21610040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.
    Franco L; Giustozzi M; Agnelli G; Becattini C
    J Thromb Haemost; 2017 Jun; 15(6):1142-1154. PubMed ID: 28316124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.
    Kearon C; Parpia S; Spencer FA; Schulman S; Stevens SM; Shah V; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Connors JM; Ginsberg JS; Spadafora L; Julian JA
    J Thromb Haemost; 2019 Jul; 17(7):1144-1152. PubMed ID: 31033194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
    Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
    BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism.
    Kearon C; Akl EA
    Blood; 2014 Mar; 123(12):1794-801. PubMed ID: 24497538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
    Verhovsek M; Douketis JD; Yi Q; Shrivastava S; Tait RC; Baglin T; Poli D; Lim W
    Ann Intern Med; 2008 Oct; 149(7):481-90, W94. PubMed ID: 18838728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated.
    Kearon C
    J Thromb Thrombolysis; 2011 Apr; 31(3):295-300. PubMed ID: 21331558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Andreozzi GM; Bignamini AA; Davì G; Palareti G; Matuška J; Holý M; Pawlaczyk-Gabriel K; Džupina A; Sokurenko GY; Didenko YP; Andrei LD; Lessiani G; Visonà A;
    Circulation; 2015 Nov; 132(20):1891-7. PubMed ID: 26408273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimal duration of anticoagulation of venous thromboembolism].
    Savina EN; Couturaud F
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
    Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
    Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian Vein Thrombosis: Incidence of Recurrent Venous Thromboembolism and Survival.
    Lenz CJ; Wysokinski WE; Henkin S; Cohoon KP; Casanegra A; Simmons BS; Saadiq RA; Daniels PR; Wysokinska EM; Bjarnason H; McBane RD
    Obstet Gynecol; 2017 Nov; 130(5):1127-1135. PubMed ID: 29016487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Duration of oral anticoagulant therapy in venous thromboembolism].
    Pinède L
    Rev Med Interne; 2001 Dec; 22(12):1225-36. PubMed ID: 11794893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis.
    Donadini MP; Ageno W; Antonucci E; Cosmi B; Kovacs MJ; Le Gal G; Ockelford P; Poli D; Prandoni P; Rodger M; Saccullo G; Siragusa S; Young L; Bonzini M; Caprioli M; Dentali F; Iorio A; Douketis JD
    Thromb Haemost; 2014 Jan; 111(1):172-9. PubMed ID: 24154729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
    Campbell IA; Bentley DP; Prescott RJ; Routledge PA; Shetty HG; Williamson IJ
    BMJ; 2007 Mar; 334(7595):674. PubMed ID: 17289685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six months
    Couturaud F; Pernod G; Presles E; Duhamel E; Jego P; Provost K; Pan-Petesch B; Sollier CBD; Tromeur C; Hoffmann C; Bressollette L; Lorillon P; Girard P; Le Moigne E; Le Hir A; Guégan M; Laporte S; Mismetti P; Lacut K; Bosson JL; Bertoletti L; Sanchez O; Meyer G; Leroyer C; Mottier D;
    Haematologica; 2019 Jul; 104(7):1493-1501. PubMed ID: 30606789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
    Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
    PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
    Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
    Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.